Author:
Inomata Shin-ichiro,Takahashi Hiroki,Nagata Manabu,Yamada Gen,Shiratori Masanori,Tanaka Hiroshi,Satoh Masaaki,Saitoh Tsukasa,Sato Toshihiro,Abe Shosaku
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference37 articles.
1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003
2. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (‘Iressa’) (IDEAL1);Douillard;Proc Am Soc Clin Oncol,2002
3. A phase II trial of ZD1839 (‘Iressa’) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL2);Kris;Proc Am Soc Clin Oncol,2002
4. Diffuse alveolar damage after ZD1839 therapy in patients with non-small cell lung cancer;Okamoto;Lung Cancer,2003
5. Sever acute interstitial pneumonia and gefitinib [Research letter];Inoue;Lancet,2003
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献